ALS, also known as Lou Gehrig’s disease, Charcot’s disease, and motor neuron disease (MND), attacks certain cells in the brain and spinal cord needed to keep muscles moving. Most people with ALS live 2-5 years after their first signs of disease. Currently, there is just a single medicine for specifically treating ALS – riluzole. The drug, marketed by Sanofi-Aventis under the name Rilutek, typically extends survival only 2 to 3 months. The determining factor for this prize is the efficacy of techniques or medications that halt the progression of ALS according to the Amyotrophic Lateral Sclerosis Functional Rating Scale.
Who’s doing Research?
Public Donation Record
|James Haight||$150||Donation to the ALS Fund|
|Alexander Neary||$300||Casting the first stone, in memory of my grandmother|